verapamil has been researched along with Colorectal Neoplasms in 15 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature." | 7.72 | Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003) |
| "Verapamil has been shown to be able to reverse development of multidrug resistance mediated by P-glycoprotein." | 5.62 | Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil. ( Gao, M; Wang, K; Wang, X; Wang, Z; Xu, X; Zhang, H, 2021) |
| "In order to determine the clinical efficacy and adverse reactions of chemotherapy and verapamil infusion through a target artery to treat colorectal cancer patients with metastasis after failure with previous conventional treatments." | 5.15 | Clinical efficacy of chemotherapy combined with verapamil in metastatic colorectal patients. ( Duan, Q; Fan, P; Hu, B; Hu, L; Li, Y; Liu, Y; Lu, Z; Lv, R; Tong, S; Zhuang, J, 2011) |
| "A Phase I trial was performed to determine the maximum tolerable dose (MTD) and dose limiting toxicities of verapamil by hepatic artery infusion, together with doxorubicin, to patients with hepatic metastases of colorectal cancer." | 5.07 | A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. ( Bertino, J; Keefe, D; Kelsen, D; Kemeny, N; Murphy, B; O'Brien, JP; Saltz, L; Tao, Y; Tong, W; Tzy-Jun, Y, 1994) |
| "5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature." | 3.72 | Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003) |
| " Saturable clearance may cause higher bioavailability and slower elimination of verapamil after acute oral overdoses." | 2.68 | Non-linear pharmacokinetics of high-dose intravenous verapamil. ( Boiocchi, M; De Cicco, M; Fantin, D; Frustaci, S; Gigante, M; Nicolosi, GL; Robieux, I; Toffoli, G, 1997) |
| "Verapamil has been shown to be able to reverse development of multidrug resistance mediated by P-glycoprotein." | 1.62 | Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil. ( Gao, M; Wang, K; Wang, X; Wang, Z; Xu, X; Zhang, H, 2021) |
| "The present study was performed to compare the cardiovascular adverse effects of verapamil, KR30031 and their optical isomers, and also to measure their ability to overcome multidrug resistance (MDR)." | 1.32 | Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. ( Choi, SU; Kwon, MJ; Lee, BH; Lee, CO; Yi, KY; Yoo, SE, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (60.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, BH | 1 |
| Lee, CO | 2 |
| Kwon, MJ | 1 |
| Yi, KY | 1 |
| Yoo, SE | 1 |
| Choi, SU | 2 |
| Wang, X | 1 |
| Wang, Z | 1 |
| Wang, K | 1 |
| Gao, M | 1 |
| Zhang, H | 1 |
| Xu, X | 1 |
| Wan, L | 1 |
| Jiao, J | 1 |
| Cui, Y | 1 |
| Guo, J | 1 |
| Han, N | 1 |
| Di, D | 1 |
| Chang, D | 1 |
| Wang, P | 1 |
| Jiang, T | 1 |
| Wang, S | 1 |
| Liu, Y | 1 |
| Lu, Z | 1 |
| Fan, P | 1 |
| Duan, Q | 1 |
| Li, Y | 1 |
| Tong, S | 1 |
| Hu, B | 1 |
| Lv, R | 1 |
| Hu, L | 1 |
| Zhuang, J | 1 |
| Mafrici, A | 1 |
| Alberti, A | 1 |
| Corrada, E | 1 |
| Ferrari, S | 1 |
| Marenna, B | 1 |
| Saltz, L | 1 |
| Murphy, B | 1 |
| Kemeny, N | 1 |
| Bertino, J | 1 |
| Tong, W | 1 |
| Keefe, D | 1 |
| Tzy-Jun, Y | 1 |
| Tao, Y | 1 |
| Kelsen, D | 1 |
| O'Brien, JP | 1 |
| Scheithauer, W | 2 |
| Kornek, G | 2 |
| Kastner, J | 1 |
| Raderer, M | 2 |
| Locker, G | 1 |
| Depisch, D | 1 |
| Pidlich, J | 1 |
| Tetzner, C | 2 |
| Purkiss, SF | 2 |
| Grahn, MF | 2 |
| Williams, NS | 2 |
| Weinländer, G | 1 |
| Hejna, M | 1 |
| Toffoli, G | 1 |
| Robieux, I | 1 |
| Fantin, D | 1 |
| Gigante, M | 1 |
| Frustaci, S | 1 |
| Nicolosi, GL | 1 |
| De Cicco, M | 1 |
| Boiocchi, M | 1 |
| Kikot', VA | 1 |
| Sorokin, BV | 1 |
| Iugrinov, OG | 1 |
| Galakhin, KA | 1 |
| Braun, EM | 1 |
| Lishchishina, EM | 1 |
| Priĭmak, VV | 1 |
| Park, SH | 1 |
| Kim, KH | 1 |
| Choi, EJ | 1 |
| Kim, S | 1 |
| Park, WK | 1 |
| Zhang, YH | 1 |
| Kim, HS | 1 |
| Jung, NP | 1 |
| Uchiyama-Kokubu, N | 1 |
| Watanabe, T | 1 |
| Cohen, D | 1 |
| Turkish, M | 1 |
| Macey, MG | 1 |
| Dalmark, M | 1 |
| Pals, H | 1 |
| Johnsen, AH | 1 |
6 trials available for verapamil and Colorectal Neoplasms
| Article | Year |
|---|---|
Clinical efficacy of chemotherapy combined with verapamil in metastatic colorectal patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 2011 |
A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Doxorubicin; Drug Resistance, Multiple; Female; H | 1994 |
Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Female; Hum | 1993 |
Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1997 |
Non-linear pharmacokinetics of high-dose intravenous verapamil.
Topics: Adenocarcinoma; Adult; Blood Pressure; Calcium Channel Blockers; Chemotherapy, Adjuvant; Colorectal | 1997 |
Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fema | 1991 |
9 other studies available for verapamil and Colorectal Neoplasms
| Article | Year |
|---|---|
Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity.
Topics: Animals; Antineoplastic Agents; Aorta; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bloo | 2003 |
Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Cell Lin | 2021 |
Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
Topics: Animals; Cell Survival; Colorectal Neoplasms; Doxorubicin; Drug Delivery Systems; HCT116 Cells; Huma | 2016 |
Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antimetabolites, Antineoplas | 2003 |
Haematoporphyrin derivative--photodynamic therapy of colorectal carcinoma, sensitized using verapamil and adriamycin.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Hematoporphyrin | 1996 |
[The use of neoadjuvant selective intra-arterial polychemotherapy and its modifier verapamil in the combined treatment of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans | 1998 |
The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Topics: Adenocarcinoma; Anticarcinogenic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bi | 2001 |
In vitro modulation of haematoporphyrin derivative photodynamic therapy on colorectal carcinoma multicellular spheroids by verapamil.
Topics: Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Hematoporphyrin Photoradiati | 1992 |